Klinische Wirksamkeit von OeKolp®


Geschützter Bereich

Liebe Besucherin, lieber Besucher,

aufgrund von Bestimmungen des Heilmittelwerbegesetzes sind wir verpflichtet, bestimmte Inhalte nur Fachkreisen zugänglich zu machen. Sie sind daher mit einem DocCheck-Login passwortgeschützt.

Anmeldung DocCheck

Sie sind bereits registriert? Dann können Sie sich mit Ihrem Username und Passwort einloggen.

Sie besitzen noch keinen Account bei DocCheck? Hier können Sie sich schnell und unkompliziert registrieren.

  • 1.

    Wolf, A. (1991). Hormonelle Altersveränderungen aus der Sicht des Gynäkologen. Fortschr Med, 109(18), S. 28-34.

  • 2.

    Haspels, A., Luisi, M., & Kicovic, P. (1981, Dec). Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas, 3(3-4), pp. 321-7.

  • 3.

    Luisi, M., Franchi, F., & Kicovic, P. (1980, Dec). A group-comparative study of effects of Ovestin cream versus Premarin cream in post-menopausal women with vaginal atrophy. Maturitas, 2(4), pp. 311-9.

  • 4.

    Henriksson, L., et al. (1994, Sep). A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol, 171(3), pp. 624-32.

  • 5.

    Bottiglione, F., Volpe, A., Esposito, G., & Aloysio, D. (1995, Nov). Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas, 22(3), pp. 227-32.

  • 6.

    Trevoux, R., van der Velden, W., & Popović, D. (1982, Apr-Jun). Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduccion, 6(2), pp. 101-6.

  • 7.

    Fink, R., et al. (1985). Vaginal oestriol - Effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol, 1(1-2), pp. 1-11.

  • 8.

    Kicovic, P., et al. (1980, Dec). The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas, 2(4), pp. 275-82.

  • 9.

    Griesser, H., et al. (2012, Apr). Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas, 71(4), pp. 360-8.

  • 10.

    De Leo, V., Caruso, S., Scolaro, V., & Cianci, A. (2009, Oct). Low dose oral contraceptives: 30 microg are still used? Minerva Ginecol, 61(5), pp. 453-8.

  • 11.

    Buhling KJ, et al. (2012). Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittel-Forschung;62(8):378-383.

  • 12.

    Clocuh, Y. (1980). Oestrogengabe als hormonelle Aufhellung zur Abklärung atrophischer Zellabstriche. Geburtsh Frauenheilk, 40, S. 1121-9.

  • 13.

    Vooijs GP, Geurts TB. (1995). Review of the endometrial safety during intravaginal treatment with estriol. European journal of obstetrics, gynecology, and reproductive biology;62(1):101-106.

  • 14.

    Weiderpass, E., et al. (1999, May). Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet, 353(9167), pp. 1824-8.

  • 15.

    Lindahl, S. (2014, Mar). Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health, 13(6), pp. 307-12.

  • 16.

    Kuhl H. (1998). Pharmakologie von Sexualsteroiden. Gynäkologe; 31:832-847.

  • 17.

    Magnusson, C., et al. (1999, May). Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer, 81(3), pp. 339-44.

  • 18.

    Rossouw JE, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA ;288(3):321-333.

  • 19.

    Anderson GL, Limacher M, Assaf AR, et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA;291(14):1701-1712.

  • 20.

    Mueck AO (2015). Anwendungsempfehlungen zur Hormonsubstitution in Klimakterium und Postmenopause. Frauenarzt 56(8):657-660.

  • 21.

    Le Ray, I., et al. (2012, Sep). Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat, 135(2), pp. 603-9.

  • 22.

    Buchholz S, et al. (2015). Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric;18(2):252-259.

  • 23.

    The 2017 hormone therapy position statement of The North American Menopause Society (2017). Menopause ;24(7):728-753.

  • 24.

    Donders, G., et al. (2014, Jun). Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat, 145(2), pp. 371-9.